Skip to main content

Table 1 Demographic and clinical characteristics of populations in the discovery and validation study

From: Increased expression of six-large extracellular vesicle-derived miRNAs signature for nonvalvular atrial fibrillation

Characteristics Discovery study Validation study
AF
(n = 12)
Non-AF
(n = 12)
P value AF
(n = 30)
Non-AF
(n = 30)
P value
Age, years (mean ± SD) 71.9 ± 6.0 69.0 ± 4.1 0.33 68.9 ± 9.1 69.2 ± 8.0 0.88
Male n, (%) 6 (50.0) 6 (50.0) 1.00 25 (83.3) 23 (76.7) 0.52
BMI (kg/m2) 24.1 ± 1.2 26.2 ± 1.3 0.22 26.4 ± 3.4 25.8 ± 3.0 0.47
Systolic BP
(mmHg)
134.5 ± 6.0 134.0 ± 5.4 0.95 136.8 ± 19.9 132.8 ± 14.3 0.38
Diastolic BP (mmHg) 78.4 ± 4.9 74.7 ± 3.2 0.53 79.1 ± 12.0 72.7 ± 10.1 0.03
Heart rate
(beats per min)
75.8 ± 3.6 86.8 ± 4.2 0.06 74.2 ± 15.3 75.4 ± 9.6 0.70
Medical history n, (%)
 Hypertension 11 (91.7) 9 (75.0) 0.27 23 (76.7) 21 (70.0) 0.56
 Diabetes mellitus 5 (41.7) 4 (33.3) 0.67 9 (30.0) 11 (36.7) 0.58
 Dyslipidemia 10 (83.3) 9 (75) 0.62 19 (63.3) 27 (90.0) 0.02
 Congestive heart failure 1 (8.3) 0(0.0) 0.31 9 (30.0) 0 (0.0) 0.001
 Stroke 1 (8.3) 0(0.0) 0.31 4 (13.3) 0 (0.0) 0.04
 Bleeding history 1 (8.3) 0(0.0) 0.31 5 (16.7) 2 (6.7) 0.23
 Smoking status
  Ex-smoker 5 (41.7) 1 (8.3) 0.06 17 (56.7) 12 (40.0) 0.33
  Current smoker 0 (0.0) 0 (0.0) 1 (3.3) 3 (10.0)
  Never smoke 7 (58.3) 11 (91.7) 12 (40.0) 15 (50.0)
Medications n, (%)
 Beta-blocker 8 (66.7) 2 (16.7) 0.01 18 (60.0) 7 (23.3) 0.004
 Calcium channel blocker 6 (50.0) 4 (33.3) 0.41 9 (30.0) 11 (36.7) 0.58
 ACE inhibitors or ARB 6 (50) 3 (25.0) 0.21 13 (43.3) 14 (46.7) 0.80
 Statin 7 (58.3) 9 (75.0) 0.39 18 (60.0) 24 (80.0) 0.09
 Warfarin 10 (83.3) 0 (0.0)  < 0.001 18 (60.0) 0 (0.0)  < 0.001
 Aspirin 0 (0.0) 0 (0.0) N/A 1 (3.3) 5 (16.7) 0.09
  1. Data presented as mean ± SD for continuous variables and frequency (percentage) for categorical variables
  2. AF atrial fibrillation, BMI body mass index, BP blood pressure, ACE angiotensin-converting enzyme, ARB angiotensin receptor blockers